General Information of Drug (ID: DMB6M3Y)

Drug Name
3-benzyloxyphenyloxoacetic acid derivative 1 Drug Info
Synonyms PMID27414413-Compound-Figure4down
Cross-matching ID
TTD Drug ID
DMB6M3Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lesinurad DMUR64T Hyperuricaemia 5C55.Y Approved [2]
Dotinurad DM0UPQJ Gout FA25 Phase 3 [3]
URC102 DMY89BN Gout FA25 Phase 2 [4]
RDEA-684 DMNWYHD Gout FA25 Phase 2 [2]
RDEA3170 DM1TKG4 Hyperuricaemia 5C55.Y Phase 2 [5]
AR882 DMFGYZ8 Gout FA25 Phase 2 [6]
Sulfonamide derivative 11 DMJBR86 N. A. N. A. Patented [1]
Cycloalkyl acid derivative 1 DMXMGSP N. A. N. A. Patented [1]
2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1 DMHYIAV N. A. N. A. Patented [1]
Tihoacetate derivative 1 DM6QHO0 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Urate anion exchanger 1 (URAT1) TTA592U S22AC_HUMAN Inhibitor [1]

References

1 Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
3 Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021 Aug;22(11):1397-1406.
4 Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
5 The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
6 Clinical pipeline report, company report or official report of Arthrosi Therapeutics